← All trials
NCT03074435
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2016
- Primary completion
- Oct 31, 2017
- Completion date
- Apr 30, 2019
- First posted
- Mar 8, 2017
- Last posted
- Mar 10, 2017
- Enrollment
- 18000
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of FranceLead sponsor
- Institut et Haute école de la Santé, La SourceCollaborator
- Government of FranceReponsible party - principal investigator
- Institut Pierre RichetCollaborator
- Government of FranceSponsor investigator
- Government of FranceOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.